High Heregulin mRNA, HER3 Linked to Poor Survival in Oropharyngeal Carcinoma
the Cancer Therapy Advisor take:
Independent associations between high heregulin messenger RNA (mRNA) and high human epidermal growth factor receptor 3 (HER3) protein levels and poor overall survival (OS) were discovered in patients with oropharyngeal squamous cell carcinoma (OPSCC), according to an article published online in the journal Cancer.
The investigators examined 96 primary tumor specimens from patients with OPSCC and analyzed for heregulin mRNA, HER3, and human epidermal growth factor receptor 2 (HER2), using in situ hybridization and immunohistochemistry, respectively.
Results showed heregulin mRNA levels greater than the median value were significantly associated with poor OS (HR, 8.48; 95% CI: 2.17, 33.17; P=0.002) but not disease-free survival (HR, 1.52; 95% CI: 0.64, 3.65; P=0.341) in patients with OPSCC.
Furthermore, a negative correlation was determined between heregulin mRNA and OS in patients with p16-positive (P=0.049) and p16-negative (P=0.091) OPSCC.
Similarly, HER3 levels greater than the median were also associated with poor OS (HR, 4.68; 95% CI: 1.47, 14.90; P=0.009) in patients with OPSCC.
An independent correlation was identified for epidermal growth factor receptor (HER) levels and disease-free survival (P=0.025), while HER was also inversely related to p16 status (P=0.012).
Using The Cancer Genome Atlas database, it was determined that head and neck squamous cell carcinoma exhibited higher levels of heregulin compared to other solid tumor types.
Associations between heregulin mRNA and HER3 protein levels and overall survival discovered in oropharyngeal squamous cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma